People · Operator

Stephen F. Snowdy

Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology

1
Companies
1
Filings
$2.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Calosyn Pharma, Inc.BiotechnologySeed$2.9M$8.5M2009
Operator network

Stephen F. Snowdy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Mike Sherman · 6 companies · 1 sharedMike ShermanRoss Barrett · 5 companies · 1 sharedRoss BarrettJoseph F. Lovett · 4 companies · 1 sharedJoseph F. LovettJoseph Lovett · 4 companies · 1 sharedJoseph LovettRoss P. Barrett · 4 companies · 1 sharedRoss P. BarrettStephen Snowdy · 4 companies · 1 sharedStephen SnowdyWilliam R. Grimes · 3 companies · 1 sharedWilliam R. GrimesJoseph P. Lovett · 2 companies · 1 sharedJoseph P. LovettRoss F. Barrett · 2 companies · 1 sharedRoss F. BarrettDavid F. Waddell · 1 companies · 1 sharedDavid F. WaddellDavid P. Waddell · 1 companies · 1 sharedDavid P. WaddellDavid Waddell · 1 companies · 1 sharedDavid WaddellMartin Becker · 1 companies · 1 sharedMartin BeckerRichard R. Babb · 1 companies · 1 sharedRichard R. BabbCalosyn Pharma, Inc. · $2.9M raisedCalosyn Pharma, Inc.Stephen F. SnowdySS
Stephen F. Snowdy Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Stephen F. Snowdy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Mike Sherman16
Ross Barrett15
Stephen Snowdy14
Joseph Lovett14
Joseph F. Lovett14
Ross P. Barrett14
William R. Grimes13
Ross F. Barrett12
Joseph P. Lovett12
David F. Waddell11
Martin Becker11
Richard R. Babb11
David P. Waddell11
David Waddell11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.